CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pandion Therapeutics, Inc., a biotechnology company developing modular protein therapeutics for autoimmune disease, today announced that Don Frail, PhD will be joining its board of directors as an independent director. He has over twenty-five years of experience in the biopharmaceutical industry focusing on both R&D and partnering.
“Don is an accomplished leader in our industry and his expertise developing innovative therapeutics will be invaluable as our pipeline moves toward the clinic,” said Rahul Kakkar, MD, chief executive officer of Pandion Therapeutics. “We welcome his guidance and insight as we bring transformative therapies to patients suffering from autoimmune diseases.”
Dr. Frail currently serves as Senior Vice President, Head of Research, External Science & Innovation, and Non-Clinical and Translational Sciences at Allergan. Previously, he served as Vice President, Science of AstraZeneca’s New Opportunities iMed/Emerging Innovations unit. Prior to AstraZeneca, Dr. Frail served in various roles at Pfizer, including CSO, Indications Discovery Unit, Vice President of Biology, and Site Head, St. Louis.
“I am excited to join the Pandion board and be part of the opportunity to apply the company’s platform to develop novel modular protein therapies,” said Dr. Frail. “I look forward to working with my fellow Board members and the Pandion team to continue to advance the important work being done by the company in the area of autoimmune diseases.”
Dr. Frail joins other members of Pandion’s board of directions including Dr. Rahul Kakkar, Alan Crane of Polaris Partners who is co-founder and Chairman of Pandion, Carlo Rizzuto, PhD, of Versant Ventures, Mitchell Mutz, PhD, of Roche Venture Fund, Jill Carroll of SR One, and Nancy Stagliano, PhD.
About Pandion
Pandion Therapeutics is developing modular biologics for autoimmune regulation that are designed to achieve lasting therapeutic outcomes for patients with autoimmune and inflammatory diseases. The company is developing its lead drug candidate, PT101, an IL-2 mutein Fc fusion protein that preferentially expands regulatory T cells, as well as a robust pipeline of systemic immune modulators and tissue-targeted therapeutics focused on the gut, liver, skin, kidneys, and pancreas. Pandion’s approach to developing modular proteins, antibodies and bispecifics includes two key elements: first, the innovative biologics are based on cutting-edge immunomodulators such as an IL-2 mutein or PD-1 agonist that work systemically by activating regulatory pathways of the immune system that suppress uncontrolled autoimmune responses; and second, these immunomodulators can be combined with tissue-selective tethers, building modular proteins and antibodies that target the precise location within the organ to deliver the desired effect. Pandion is backed by leading life sciences investors including Polaris Partners, Versant Ventures, Roche Venture Fund, SR One, BioInnovation Capital, and the JDRF T1D Fund. The company is headquartered in Cambridge, Massachusetts. Please visit www.pandiontx.com.
